KAPRUVIA®
(difelikefalin) Injection

ALGORITHM FOR THE SCREENING, DIAGNOSIS, ASSESSMENT AND TREATMENT OF CKD-aP IN PATIENTS ON HAEMODIALYSIS[1]



Adapted from Agarwal R et al, 2023[1]

Please note: difelikefalin is the only licensed treatment for moderate-to-severe CKD-aP in adult patients on in-centre haemodialysis. Other pharmacological treatments in the proposed algorithm are off-label. Please refer to the relevant Summary of Product Characteristics before making prescribing decisions.

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd. Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com

Prescribing Information and Adverse Event Reporting
Scan the QR code or click here

Ca, calcium; **CKD**, chronic kidney disease; **CKD-aP**, chronic kidney disease-associated pruritus; **P**, phosphorus; **PTH**, parathyroid hormone; **QoL**, quality of life; **SADS**, self-assessed disease severity; **SSRI**, selective serotonin re-uptake inhibitor; **WI-NRS**, worst itch numerical rating scale; **UVB**, ultraviolet B.

References: 1. Agarwal R, et al. *Clin Kidney J.* 2023;16:30–40.

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

UK-DFK-2500016 | April 2025

CSL Vifor